We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer (ETAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02584985
Recruitment Status : Recruiting
First Posted : October 23, 2015
Last Update Posted : January 23, 2019
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:

Standard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity. Laparoscopic approach has been validated by several randomised controlled trials: laparoscopic approach offers to the patient a better post-operative recovery, a lower risk of wound hernia and comparable oncological results. However, the risk of conversion to open procedure remains significant.

Endoscopic Transanal Proctectomy allows retrograd mesorectal excision, performing the whole pelvic dissection via a specific-moderate cost device. The procedure is then completed by a briefer transabdominal laparoscopic step to mobilise the colon and perform inferior mesenteric vessels ligation, prior to low coloanal anastomosis. The originality of this approach is to perform a surgical dissection via an extra peritoneal route, without peritoneal and abdominal wound trauma. This focuses on new technical improvement in the area of mini-invasive pelviabdominal surgery using natural orifice as surgical access. This approach offer closer and better exposure of pelvic dissection plane and could improve oncological quality and pelvic nerve preservation. It could be profitable to postoperative patient outcome. However rates and type of cancer-recurrences as well as functional results have to be assessed in a controlled study. This technique has shown to be feasible and reproducible through early clinical series. Conversion rates appear to be lower than published rates of laparoscopic approach, markedly inferior to 10%. Compiled rates of morbidity (27.8%), R1 resection* (6%), mesorectum macroscopic integrity (100%) appear to be comparable to laparoscopic approach results. However functional results as well as urologic morbidity have to be evaluated in comparative studies. In a preliminary retrospective comparative (n=72) we founded comparable oncological quality criteria (R1 resection 5.9% vs 10.5% p 0.74, Grade 3 mesorectal integrity 57.5 vs 56.2 p 0.99), lower conversion rate to open procedure (2.9% vs 23.6% p 0.011), shorter in-hospital stay (8 vs 9 days p 0.038). Comparable morbidity rates (Dindo 1-4 27% vs 34% p 0.52) and functional results (Kirwan 1/2 80.3% vs 80.6% p 0.94) were also founded. These data need to be confirmed. To this date, Endoscopic Transanal Proctectomy has been evaluated through preliminary studies including several short series demonstrating the feasibility of the technique and showing low morbidity. For some authors the benefit of transanal approach is significant in difficult cases such as male patient and narrow pelvis. Very recently, two non randomised comparative studies were published with conclusions close to those in our study.

Investigators propose, with the support of the GRECCAR group, to conduct a national, multicenter, open-label randomized study based on oncological non-inferiority (R1 resection rate) for the main objective, comparing Endoscopic Transanal Proctectomy to Standard Transabdominal Laparoscopic Proctectomy, for low lying rectal cancer requiring manual colo-anal anastomosis. There is a clear expected benefit expected for the patients through the ETAP procedure in term of post operative short term outcome, risk of conversion to open procedure, risk of wound hernia.This trial could also show significant advantages in terms of quality of dissection, quality of the specimen, quality of nerve preservation.

Condition or disease Intervention/treatment Phase
Rectal Cancer Procedure: ETAP Procedure: Standard Transabdominal Laparoscopic Proctectomy Phase 3

Detailed Description:
The main objective of study is to assess if R1 resection rate of Endoscopic Transanal Proctectomy (ETAP) is not meaningfully inferior to Standard Laparoscopic TME for low lying rectal cancer requiring manual colo-anal anastomosis. The secondary objective will evaluate conversion rate, mini invasive level of abdominal approach postoperative morbidity, In hospital length of stay, Mesorectum macroscopic assessment, Functional urologic and sexual results, Fecal Continency, global QoL, stoma-free survival, disease-free survival at 3 years. Patients with non metastatic rectal adenocarcinoma requiring coloanal anastomosis will be considered for the study. Based on the non-inferiority hypothesis, the population estimated in this study at 226 patients, 113 for each arm. Inclusion period will be 3 years, the study will be running for 6 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 226 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11)
Actual Study Start Date : January 2016
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
ETAP : Endoscopic Transanal Proctectomy
  1. Primary transanal approach :

    Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).

  2. Secondary transabdominal approach :

Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction.

Procedure: ETAP
Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach

Standard Transabdominal Laparoscopic proctectomy
Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
Procedure: Standard Transabdominal Laparoscopic Proctectomy
Primary transabdominal laparoscopic approach

Primary Outcome Measures :
  1. R1 resection rate [ Time Frame: from surgery up to 3 years ]
    R1 resection rate defined as circumferential resection margin (CRM) ≤ 1 mm, distal or positive margin (and the complete rectal resection meso levels (grade III) as classified by Quirke).

Secondary Outcome Measures :
  1. Failure rate (conversion to open) [ Time Frame: During surgery ]
  2. Disease-free survival at 3 years [ Time Frame: 3 years from surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non metastatic stadified T3 rectal adenocarcinoma allowing sphincter-sparing procedure
  • Tumor location or local condition justifying manual coloanal anastomosis
  • Age >18 years
  • Patient eligible for surgery
  • Written informed consent
  • Affiliation to Social Security System

Exclusion Criteria:

  • Tumor stadified T4 with en-bloc resection
  • Possible mechanical trans-sutural anastomosis
  • Distant metastasis at diagnosis
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule
  • Patients deprived of liberty or placed under the authority of a tutor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02584985

Layout table for location contacts
Contact: Genre Dominique, MD 33 (0)4 91 22 37 78 drci.up@ipc.unicancer.fr
Contact: Cournier Sandra 33 (0)4 91 22 37 78 drci.up@ipc.unicancer.fr

Layout table for location information
Institut Paoli-Calmettes Recruiting
Marseille, France, 13009
Contact: GENRE Dominique, MD    33(0) 4 91 22 37 78    drci.up@ipc.unicancer.fr   
Contact: COURNIER Sandra    33(0) 4 91 22 37 78    drci.up@ipc.unicancer.fr   
Principal Investigator: LELONG Bernard, MD         
Sponsors and Collaborators
Institut Paoli-Calmettes
Layout table for investigator information
Principal Investigator: LELONG Bernard, MD Institut Paoli-Calmettes
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT02584985    
Other Study ID Numbers: ETAP-GRECCAR 11-IPC 2015-005
First Posted: October 23, 2015    Key Record Dates
Last Update Posted: January 23, 2019
Last Verified: January 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases